Natural Capsules Limited has announced a significant manufacturing partnership through its material subsidiary, Natural Biogenex Private Limited (NBPL), which has entered into framework and contract manufacturing agreements with Fermbox Bio Private Limited. The collaboration aims to strengthen fermentation-based Contract Development and Manufacturing Organization (CDMO) capabilities in the biotechnology sector.

Agreement Structure and Investment Details

The strategic partnership involves substantial investment and infrastructure utilization at Natural Biogenex's facility in Tumkur. Under the comprehensive agreement, Fermbox Bio will provide advanced fermentation technology and equipment placement while NBPL will handle licensed manufacturing, quality assurance, and regulatory compliance.

Management Commentary and Strategic Vision

Managing Director Mr. Sunil Laxminarayana Mundra highlighted the partnership's significance, stating that this collaboration marks a pivotal step for Natural Biogenex and the Natural Capsules Group in expanding into high-value, fermentation-based bio-manufacturing CDMO services for pharma and allied products. The partnership combines NBPL's licensed manufacturing strength and regulatory excellence with Fermbox's advanced technology, enabling value-accretive, scalable growth in both pharmaceutical and industrial biotech segments.

Market Positioning and Growth Opportunities

The partnership positions the company to serve global biotechnology and biopharma clients with integrated manufacturing capabilities. The collaboration is strategically aligned with the growing global biotech and biopharma CDMO market, which continues to present strong growth opportunities driven by rising demand, increasing outsourcing, and more complex biomanufacturing requirements.

Regulatory Compliance and Corporate Structure

The company has fulfilled its regulatory obligations by disclosing this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Natural Biogenex Private Limited operates as a material subsidiary of Natural Capsules Limited, and the agreement represents a strategic partnership where no share issuance or equity participation is involved in the transaction.

This manufacturing partnership demonstrates Natural Capsules' strategy to optimize subsidiary operations through strategic collaborations, enabling better utilization of existing infrastructure while attracting external investment for capacity enhancement in the high-growth biotechnology manufacturing sector.

Natural Capsules Limited has released its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company's Board of Directors approved these results on February 13, 2026, based on recommendations from the Audit Committee.

Q3 FY25 Standalone Performance

The company's standalone financial performance for the third quarter of FY25 showed the following results:

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Natural Capsules demonstrated strong operational performance:

Consolidated Results Overview

The consolidated financial results for Q3 FY25 showed total income from operations of ₹146.41 crore and net profit after tax of ₹55.03 crore. For the nine-month period, consolidated total income reached ₹447.73 crore with net profit of ₹201.94 crore.

Financial Position and Capital Structure

The company maintains a stable capital structure with equity share capital of ₹27.13 crore (face value ₹5 per share) remaining consistent across reporting periods. Other equity stood at ₹254.46 crore as of December 31, 2025, resulting in a net worth of ₹281.59 crore. The debt-equity ratio remained low at 0.07.

Business Segments and Operations

Natural Capsules operates in reportable business segments including "Latex Rubber Thread" and "Corrugated Carton Box." The company's subsidiary, Premier Tissues India Limited, operates in the "Paper Tissue" segment. The consolidated results for the nine months ended December 31, 2025, include the financial results of this wholly-owned subsidiary.

Regulatory Compliance and Governance

The company reported no pending investor complaints at the beginning of the quarter. One complaint was received and resolved during the quarter, with no complaints pending at the quarter's end. The financial results were reviewed by the audit committee and approved by the Board of Directors, with auditors issuing an unmodified opinion on the same.

Source: Natural Capsules Limited Financial Results